Chemed stock
CHENYSEChemed Corporation, HealthcareISIN US16359R1032
75Score 75 out of 100, Strong
Price and trend
87 / 100
Price history
+23% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 18% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is at its 52-week high. Largest decline in 20 years: 55% (July 2007 to October 2008).
Chart figures for advanced users
- SMA 50$516.61
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$467.00
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$368.59
- The lowest closing price of the last twelve months.
- Resistance$552.72
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Chemed Corporation belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $7.16B, is number 14 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.53B (up 4.1% year on year) and earnings of $265.24M (down 12.2%).
- For fiscal 2026, analysts expect on average revenue of $2.73B (up 8%) and adjusted earnings per share of $25.78 (up 19.4%).
Show more
- MEQIRI Score 75 out of 100 (Strong): rank 68 of 714 in Healthcare, median 53.
- The P/E is 25.6 (Medical (Care Facilities) median 19.4, own median of recent years 28.6).
- Our model puts fair value at $512.19, with the price 8% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 26 years.Capital allocation 94
- High return on capitalReturn on invested capital 23.7% in fiscal 2025, Medical (Care Facilities) median 6.1%.Profitability 77
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 97
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and capital allocation, while valuation and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $394.00 and expensive above $731.71 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $608.15 (cash-flow model) and $416.24 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $460.04, at 7.8% it would be $590.55.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.2% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 30%, operating 13%, net 10%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 27 Oct 2026EPS reported $6.75 (expected $6.44)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $25.78+1.1%
- Revenue
- $2.73B+0.5%
- Earnings per share
- $27.85+1.2%
- Revenue
- $2.91B+1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +6.4%Chemed now expects to finish 2026 at or slightly above the high end of its prior adjusted EPS guidance, driven by stronger performance at VITAS.
“We expect this pattern to continue for the remainder of 2026 and all of 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $7.22M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Mcnamara Kevin JSale
3 Nov 2026, president and CEO
- Shares
- 2,000
- Price
- $537.90
- Value
- $1.08M
- Lee Spencer SSale
2 Nov 2026, executive vice president
- Shares
- 920
- Price
- $537.17
- Value
- $494,196
- Mcnamara Kevin JSale
28 Sept 2026, president and CEO
- Shares
- 2,000
- Price
- $513.45
- Value
- $1.03M
Show 7 more
- Mcnamara Kevin JSale
18 Sept 2026, president and CEO
- Shares
- 2,000
- Price
- $501.40
- Value
- $1M
- Lee Spencer SSale
21 Aug 2026, executive vice president
- Shares
- 1,000
- Price
- $541.04
- Value
- $541,040
- Mcnamara Kevin JSale
21 Aug 2026, president and CEO
- Shares
- 2,000
- Price
- $541.16
- Value
- $1.08M
- Mcnamara Kevin JSale
3 Aug 2026, president and CEO
- Shares
- 2,000
- Price
- $539.51
- Value
- $1.08M
- Grace Patrick PSale
31 Jul 2026, Board
- Shares
- 190
- Price
- $532.00
- Value
- $101,080
- Lindell Andrea RSale
9 Jun 2026, Board
- Shares
- 1,347
- Price
- $447.33
- Value
- $602,554
- Walsh George J IiiSale
29 May 2026, Board
- Shares
- 500
- Price
- $437.83
- Value
- $218,915
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Chemed
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 75
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- DaVitaDVA $11.54B67
- Ensign GroupENSG $10.86B66
- Max Healthcare InstituteMAXHEALTH.NS $9.64B53
- PACS GroupPACS $7.95B67
- Fortis HealthcareFORTIS.NS $6.22B53
- Concentra Group Holdings ParentCON $5.5B69
- LifeStance Health GroupLFST $5.46B57
- Option Care HealthOPCH $4.75B64
ETFs that hold Chemed
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.58% | 0.40% | €807M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.21% | 0.30% | €5.27B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.12% | 0.39% | €188.08M |
Show 5 more
| Franklin U.S. Equity UCITS ETFFLXU | 0.10% | 0.20% | €55.89M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.08% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.07% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.07% | 0.30% | €944.34M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.03% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.